...
...
Next Story

Covid-19: PM virtually reviews vaccine progress of 3 more pharma companies

PM Modi also discussed matters related to regulatory approvals of the vaccine candidates

Updated on: Nov 30, 2020, 17:09:22 IST
Hindustan Times, New Delhi | By
Prefer HTon Google
Advertisement

Prime Minister Narendra Modi on Monday had virtual meetings with three teams working on developing and manufacturing vaccine for coronavirus disease (Covid-19).

Prime Minister Narendra Modi. (File photo)
Prime Minister Narendra Modi. (File photo)

These teams were from Gennova Biopharmaceuticals Ltd in Pune, Biological E Ltd, and Dr Reddy’s Laboratories Ltd, in Hyderabad, according to the statement released by PMO.

“The PM appreciated the efforts being taken by the scientists in these companies to come out with a vaccine solution to tackle Covid-19. The potential of various platforms for vaccine development was also discussed,” the statement read.

PM Modi also discussed matters related to regulatory approvals of the vaccine candidates. “PM also asked the companies to come out with their suggestions and ideas regarding the regulatory processes and related matters,” the statement said.

Also read | With 140 million Covid-19 tests, India crosses major landmark

The PM also suggested the companies to have a vaccine outreach initiative in place for the general public so as to dispel myths or doubts about it.“He suggested that they should take extra efforts to inform the general public in simple language about the vaccine and related matters such as its efficacy etc,” read the statement.

Dr Reddy’s Laboratories has tied up with the Russian Covid-19 vaccine developers to conduct phase 2/3 clinical trials for their Sputnik V in India.

Biological E has also recently started phase 1/2 clinical trials of its Covid-19 vaccine candidate.

Gennova Biopharmaceuticals is also ready to test its m-RNA vaccine candidate against Covid-19.

On Saturday, PM Modi had taken a three-city tour to physically review progress at three companies that are in advanced stages of developing and testing Covid-19 vaccine candidate. The companies he visited were Zydus Cadila in Ahmadabad, Bharat Biotech in Hyderabad, and Serum Institute of India in Pune.

 
ABOUT THE AUTHOR
Rhythma Kaul

Rhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.

Get the latest India News, breaking headlines and real-time updates from across the country. Stay informed about politics, government policies, crime, weather and major national developments.
Get the latest India News, breaking headlines and real-time updates from across the country. Stay informed about politics, government policies, crime, weather and major national developments.
SHARE THIS ARTICLE ON
Hindustantimes wants to start sending you push notifications. Click allow to subscribe